BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $2,746,000 | -62.7% | 45,361 | -68.0% | 0.12% | -66.1% |
| Q1 2017 | $7,358,000 | -18.4% | 141,887 | -30.3% | 0.36% | -50.5% |
| Q4 2016 | $9,021,000 | +889.1% | 203,449 | +961.3% | 0.73% | +1246.3% |
| Q3 2016 | $912,000 | -85.9% | 19,170 | -86.6% | 0.05% | -85.5% |
| Q2 2016 | $6,456,000 | +597.9% | 142,774 | +534.4% | 0.37% | +482.8% |
| Q1 2016 | $925,000 | -87.7% | 22,505 | -88.6% | 0.06% | -87.6% |
| Q4 2015 | $7,527,000 | +111.9% | 197,303 | +82.5% | 0.52% | +142.7% |
| Q3 2015 | $3,552,000 | -94.1% | 108,133 | -87.5% | 0.21% | -93.7% |
| Q2 2015 | $60,314,000 | +596.3% | 862,493 | +582.1% | 3.39% | +540.1% |
| Q1 2015 | $8,662,000 | +252.7% | 126,452 | +277.3% | 0.53% | +163.2% |
| Q4 2014 | $2,456,000 | -60.9% | 33,512 | -61.4% | 0.20% | -61.0% |
| Q2 2014 | $6,282,000 | +706.4% | 86,892 | +720.9% | 0.52% | +275.9% |
| Q1 2014 | $779,000 | -76.0% | 10,585 | -77.4% | 0.14% | -67.5% |
| Q4 2013 | $3,251,000 | -10.6% | 46,748 | -15.6% | 0.42% | -37.6% |
| Q3 2013 | $3,636,000 | +88.8% | 55,358 | +99.1% | 0.68% | +135.5% |
| Q2 2013 | $1,926,000 | – | 27,804 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |